P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Investigation of the impact of HLA-DPB1 matching status in 10/10 HLA matched unrelated hematopoietic stem cell transplantation: results of a French single center study.
Cyrille Touzeau,Katia Gagne,Véronique Sébille,Patricia Herry,Patrice Chevallier,Gilles Folléa,Anne Devys,Philippe Moreau,Mohamad Mohty,Anne Cesbron Gautier +9 more
TL;DR: Outcome analysis revealed that TCE3 and TCE4 non-permissive HLA-DPB1 disparities were not associated with worsened overall survival, relapse risk neither risk of acute GvHD.
Journal ArticleDOI
Pomalidomide in the management of relapsed multiple myeloma.
Cyrille Touzeau,Philippe Moreau +1 more
TL;DR: The present review addresses current knowledge regarding the clinical use of pomalidomide in relapsed myeloma patients by assessing it in triplet combinations with other antimyeloma agents.
Journal ArticleDOI
Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.
Cyrille Touzeau,Amrita Krishnan,Philippe Moreau,Aurore Perrot,Saad Z. Usmani,Salomon Manier,Michele Cavo,Carmen Martínez-Chamorro,Ajay K. Nooka,Thomas R. Martin,Lionel Karlin,Xavier Leleu,Nizar J. Bahlis,Britta Besemer,Lixia Pei,Raluca I. Verona,Suzette Girgis,Clarissa M. Uhlar,Rachel Kobos,Alfred L. Garfall +19 more
TL;DR: Initial results of serial targeting of BCMA with tec following ADC or CAR-T tx suggest a promising ORR with responses occurring early and deepening over time, with no new safety concerns.
Journal ArticleDOI
Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup
Antonio Palumbo,Meletios A. Dimopoulos,Philippe Moreau,Wee Joo Chng,Hartmut Goldschmidt,Roman Hájek,Thierry Facon,Heinz Ludwig,Ludek Pour,Ruben Niesvizky,Albert Oriol,Laura Rosiñol,Aleksandr Suvorov,Gianluca Gaidano,Tomas Pika,Katja Weisel,Vesselina Goranova-Marinova,Heidi H. Gillenwater,Nehal Mohamed,Shibao Feng,Douglas E. Joshua +20 more
TL;DR: A preplanned subgroup analysis of efficacy and safety outcomes of the ENDEAVOR study according to age found PFS was improved with Kd vs Vd within each age subgroup, and ORRs in each age group were also higher in the Kd arm compared with the Vd arm in each subgroup.
Journal ArticleDOI
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
Philippe Moreau,Benjamin Hebraud,Thierry Facon,Xavier Leleu,Cyrille Hulin,Mahmoud Hashim,Yannan Hu,Denis Caillot,Lofti Benboubker,Sonja Zweegman,Maximilian Merz,Katja Weisel,Hans Salwender,Elias K. Mai,Hartmut Goldschmidt,Uta Bertsch,Veronique Vanquickelberghe,Tobias Kampfenkel,Carla de Boer,Stanimira Krotneva,Irina Proskorovsky,Jianming He,Annette Lam,Charlene Lee,Sarah Cote,Pieter Sonneveld +25 more
TL;DR: This analysis supports front-line daratumumab for transplant-eligible newly diagnosed multiple myeloma and no significant PFS/OS differences were seen for VTd versus other SoC.